A careful tracking guide for recombinant human growth hormone, focused on what to monitor when using a prescription compound with real metabolic consequences.
At a glance
Somatropin is recombinant human growth hormone — the actual hormone, identical to what the pituitary produces, manufactured as a 191-amino-acid protein. It is a prescription drug used for pediatric and adult GH deficiency, AIDS-associated wasting, short bowel syndrome, and a small set of other approved indications. Off-label use for body composition or anti-aging exists but is more regulated than any other compound in this series, and the risk profile justifies more cautious tracking.
Somatropin acts directly on GH receptors throughout the body, raising IGF-1 production in the liver and producing the full suite of GH effects: lipolysis, modest protein anabolism, insulin antagonism, fluid retention, and effects on connective tissue. Unlike sermorelin or GHRH analogs, somatropin bypasses the pituitary entirely — there is no pulsatile control, no negative feedback through the hypothalamus. The dose you inject is the dose your tissues see.
Clinical protocols for adult GH deficiency use very small daily subcutaneous doses, titrated to keep IGF-1 in the age-appropriate range, not pushed above it. Off-label protocols for body composition often use larger doses, which is also where the side-effect profile becomes meaningful. Time of injection varies — morning, evening, and split dosing all have advocates. Daily dosing is more common than every-other-day for steady IGF-1.
Therapeutic-dose somatropin produces measurable but slow changes — improved body composition over months, often better sleep quality, often better skin and recovery. Off-label higher doses do produce more dramatic body composition changes but also reliably produce insulin resistance, water retention, joint pain, and over time, organ growth that is not aesthetic. IGF-1 in the upper-normal range is the conservative target; pushing well above it has consistent downside data.
In Peptide IA, a daily log of units injected, injection time, fasting glucose, and a swelling/tingling checkbox. Weekly: blood pressure, waist measurement, and an average glucose. Quarterly: IGF-1, HbA1c, and lipids attached. The picture you want is IGF-1 stable inside the target range with fasting glucose unchanged from baseline. If glucose is drifting up, the protocol is asking too much of your metabolism.
Somatropin is a prescription drug for good reason. Contraindications include active malignancy, active diabetic retinopathy, critical illness, and pregnancy. Diabetes risk is real and dose-dependent. Cardiac hypertrophy with sustained high-dose use has clinical evidence. Use of this compound without a prescribing clinician and regular bloodwork is not something we can support — the gap between therapeutic and harmful is narrower than with most peptides on this list.
If you are using somatropin, treat it like the prescription endocrine drug it is. Track daily glucose, get bloodwork on schedule, target the conservative end of IGF-1, and have a clinician in the loop. The tracking discipline is not optional.
Peptide IA is an educational and self-tracking tool. Nothing in this post is medical advice. Doses mentioned reflect what is commonly reported in research literature — they are not recommendations. Always consult a qualified physician before starting, changing, or stopping any protocol.